Breast Cancer Clinical Trial
Official title:
Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care
| Verified date | February 2015 |
| Source | Brigham and Women's Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Institutional Review Board |
| Study type | Interventional |
Growing evidence and understanding of an inherited component to several common, chronic
diseases has led to an increase in the importance of information about family health
history, and the integration of this information with other risk factors for common
diseases, like lifestyle risk factors. The US Preventive Services Task Force (USPSTF)
recommends the use of family health history as a routine genetic screening test for common
diseases, as obtaining a complete family health history is the first step to identifying
patients who are in need of intervention (e.g., intensive screening, lifestyle modification,
preventative therapies, genetic counseling). The importance of integrating family health
history with an individual's medical record will increase as our understanding of the genome
evolves because it will be more essential to put detailed personal genetic information into
a clinical context. Because of limited time during a typical primary care visit, and the
concerns of primary care providers (PCPs) about their self-efficacy of estimating and
providing guidance about risk, PCPs frequently do not obtain a family health history or
provide individualized risk assessment. These issues highlight the need to leverage
technology to collect these data independent of clinic visits, yet have these data
interoperate with an individual's electronic health record (EHR). Telephonic interactive
voice response systems (IVRS) and self-administered web-based tools are a low-cost,
sustainable way of reaching out to primary care populations, independent of a visit. We
propose to develop, implement, and evaluate a patient-reported, EHR-integrated personalized
risk assessment module to provide tailored disease risk and risk reduction information.
The Specific Aims of the proposed project are to: Aim 1: Develop a patient-reported,
EHR-integrated, personalized risk assessment module to provide tailored disease risk and
risk reduction information for four common diseases (breast cancer, colorectal cancer,
coronary heart disease, and type II diabetes) for the patient and his/ her PCP. Aim 2:
Measure the reach and effectiveness of this integrated risk assessment module by conducting
a cluster randomized controlled trial (RCT) of adult primary care patients in the Brigham
and Women's Primary Care Practice-Based Research Network. Aim 3: Evaluate facilitators and
barriers to the adoption and implementation of this integrated risk assessment module.
This project will further our understanding of how technology can be used to fill a gap in
current clinical practice by facilitating the systematic collection of family health history
and lifestyle risk factor data and integrating these data with an individual's EHR to
personalize care in a variety of settings and for diverse patient populations. This work
will use current national data standards for interoperability, and lessons learned from this
project will be exportable to healthcare settings throughout the United States.
| Status | Completed |
| Enrollment | 6075 |
| Est. completion date | December 2014 |
| Est. primary completion date | December 2014 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 75 Years |
| Eligibility |
Inclusion Criteria: - Adults 18 - 75 Years old - English or Spanish speaking - Recent visit to a participating primary care practice |
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| United States | Brigham and Women's Hospital | Boston | Massachusetts |
| Lead Sponsor | Collaborator |
|---|---|
| Brigham and Women's Hospital |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | documentation of family history in coded fields in the patient's electronic health record | 3 months following primary care visit | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |